Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the ...
Business Insider5d
Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China ...
Business Wire5d
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the ...
Nasdaq5d
Zai Lab, Vertex Ink Stategic Deal For Povetacicept In China And The Broader Area
(RTTNews) - Zai Lab Limited (ZLAB), a biopharmaceutical company, and Vertex Pharmaceuticals Inc. (VRTX), a biotechnology company, on Friday, announced an exclusive collaboration and licensing ...
Yahoo Finance2d
Vertex Pharmaceuticals Incorporated (VRTX)
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in mainland China ...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will ...
Business Wire5d
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the ...
Le Lézard5d
Alphyn to Present at Upcoming Investor Conferences
Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present at the following investor conferences during J.P.
Le Lézard6d
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology ...
The Pharma Letter4d
Vertex out-licenses povetacicept to Zai Lab
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Quanterix (QTRX) and Walgreens Boots Alliance (WBA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report), Quanterix ...
Hosted on MSN6d
Vertex and Orna sign partnership to improve efficiencies of gene therapies
Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.